Sorbent Therapy of the Cutaneous Porphyrias

Completed · Phase 2/Phase 3

Conditions studied: Erythropoietic Protoporphyria

In brief

The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).

Key facts

Study ID

NCT01422915

Run by

Brigham and Women's Hospital

People needed

4

Starts

2011-05-01

Expected to finish

2012-03-01

Last updated by the study team

2017-04-25

Who can join

Age: 22 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult over age 21
• healthy

You may not qualify if…

• Intercurrent illness
• pregnancy

Where it is running

• Brigham & Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.